Cite

HARVARD Citation

    Mahlangu, J. et al. (2023). A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. British journal of haematology. pp. 229-239. [Online]. 
  
Back to record